Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
Nov. 5 — The FDA Nov. 5 approved Genvoya as a complete regimen for treating HIV-1 infection in adults and pediatric patients who are at least 12 years old.
Genvoya is a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide.
The product, which is marketed by Gilead Sciences Inc., is approved for HIV-infected adults and children who are at least 12 years old and weigh at least 77 pounds (35 kilograms) and who have never taken HIV therapy, and HIV-infected adults whose HIV-1 virus is currently suppressed, the Food and Drug Administration said. While Genvoya isn't recommended for patients with severe renal impairment, those with moderate renal impairment may take it.
The FDA said the product contains a new form of tenofovir that hasn't been approved before. This new form provides lower levels of drug in the bloodstream, but higher levels within the cells where HIV-1 replicates, the agency said.
The product was developed to help reduce some drug side effects, the agency said. Genvoya appears to be associated with less kidney toxicity and decreases in bone density than previously approved regimens including tenofovir, based on laboratory measures.
“Today’s approval of a fixed dose combination containing a new form of tenofovir provides another effective, once daily complete regimen for patients with HIV-1 infection,” said Edward Cox, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.
Genvoya’s safety and effectiveness in adults were evaluated in 3,171 participants enrolled in four clinical trials, the FDA said. Depending on the trial, participants were randomly assigned to receive Genvoya or another FDA-approved HIV treatment.
Results showed Genvoya was effective in reducing viral loads and comparable to the other treatment regimens, the agency said.
Patients receiving Genvoya experienced greater increases in serum lipids (total cholesterol and low-density lipoprotein) than patients receiving other treatment regimens in the clinical studies, the FDA said.
Genvoya carries a boxed warning alerting patients and health-care providers that the drug can cause a buildup of lactic acid in the blood and severe liver problems, both of which can be fatal, the agency said. The boxed warning also says that Genvoya isn't approved to treat chronic hepatitis B virus infection.
The most common side effect is nausea, the FDA said. Serious side effects include new or worsening kidney problems, decreased bone mineral density, fat redistribution and changes in the immune system (immune reconstitution syndrome).
Health-care providers are advised to monitor patients for kidney and bone side effects, the agency said. Genvoya shouldn't be given with other antiretroviral products and may have drug interactions with a number of commonly used medications.
To contact the reporter on this story: Bronwyn Mixter in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Lee Barnes at email@example.com
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)